The surge of GLP-1 therapies has transformed metabolic health and weight loss into one of the fastest-growing areas in medicine. Companies such as Novo Nordisk and Eli Lilly have led the way with drugs that are redefining how patients manage obesity and Type 2 diabetes.
But drug innovation alone is no longer enough. Payers, regulators, and providers increasingly demand real-world outcomes data, and patients expect a digital app alongside their therapy.
This is why GLP-1 companion app development has become a strategic priority, and why a regulatory-ready companion app, built on the right foundation, is now a competitive necessity rather than a nice-to-have.
Below, we examine common pain points for pharmaceutical companies developing drugs in the metabolic healthcare space, how a GLP-1 companion solution can help your company gain a competitive edge with payers and patients, and why the NEX platform is crucial for creating this app without exceeding your budget or prolonging your product launch.
Common Pain Points in the Pharma & GLP-1 Market
The vast opportunities available in the GLP-1 space are undeniable. But so are the barriers to getting a digital solution off the ground. Most companies encounter the same roadblocks, including:
1. A Lack of Real-World Evidence
Clinical trial data is powerful, but payers and regulators want proof of real-world outcomes, that is, data that shows how therapies work across broad patient populations. Without a digital mechanism to collect and analyze this data, pharma companies risk slower reimbursement and limited market access.
2. Fragmented Data Collection
Patients often use different biosensors, apps, and wearables, which leads to fragmented and inconsistent data streams. This makes it nearly impossible to get a unified view of patient outcomes, adherence, or engagement over time.
3. Regulatory and Data Security Complexity
Building a compliant, secure, and scalable software stack from scratch can take 12 to 24 months. All the while, this process consumes capital while delaying strategic launches. Most pharmaceutical companies lack in-house software expertise to navigate these requirements efficiently.
4. Reimbursement Pressures
Payers increasingly require outcome data to justify coverage for high-cost therapies. Without a robust way to demonstrate value, even clinically successful products can face reimbursement delays or denials.
These pain points collectively slow time to market, limit patient impact, and weaken competitive positioning. A GLP-1 companion app can address each of these challenges, but only if it is built on the right foundation.
How the NEX Platform Solves These Challenges
Pharma companies shouldn’t have to build custom digital platforms for every new therapy they create. NEX, a rapid product delivery platform for medtech, was built to remove that burden. This customizable medtech software platform is device-agnostic, regulatory-ready, and designed to accelerate the development of connected health solutions. It is especially useful in fast-moving markets like GLP-1 therapies.
The NEX Platform by Sequenex can help your company get ahead of the competition thanks to its long list of beneficial features, including:
1. Device-Agnostic Integration
NEX integrates with continuous glucose monitors (CGMs) and other biosensors, making it easy to gather data from diverse devices. This is crucial for the metabolic health sector, where patients may already be using different wearables and connected devices to track their progress.
2. Fast Deployment Timeline
Instead of waiting 12 to 18 months to build from scratch, pharma companies can launch branded GLP-1 companion apps in just a few months. This reduced time to market can help position your product as a market leader in a highly competitive and rapidly evolving space.
3. Regulatory Readiness Built In
NEX, developed under an ISO 13485:2016 Quality Management System, comes with built-in frameworks aligned to FDA expectations and global privacy regulations. That means compliance, data security, and documentation are already in place. This built-in readiness significantly reduces risk while accelerating approval timelines.
4. Outcomes-Driven Architecture
Our platform is designed to collect, visualize, and analyze patient data in real time. This empowers pharma teams to build compelling evidence for payers, support reimbursement strategies, and continuously improve patient engagement.
With NEX, companies can shift their energy from building software to launching solutions and driving measurable outcomes.
Strategic Advantages for Pharma & Prescribing Clinics
The benefits of launching a GLP-1 companion app on NEX go far beyond technology. Our platform has the potential to unlock strategic leverage across your entire business model, providing a necessary advantage in a lucrative healthcare space overcrowded with competition.
With NEX on your side, you can expect to:
Accelerate Your Market Entry
Launching faster means you can capitalize on the momentum of the GLP-1 surge while competitors are still getting started. Early movers will establish a dominant position in this rapidly expanding market.
Scale Your Patient Engagement Efficiently
A branded companion app gives you direct engagement with patients. This means more adherence data, better outcomes tracking, and more opportunities to personalize the patient experience and improve your offerings to grow your reach.
Generate Robust Outcomes Evidence
By capturing real-world data from biosensors, NEX provides a powerful evidence base to support payer negotiations and regulatory submissions. This aspect is vital for strengthening both clinical and commercial cases.
Lower Your Development Costs
Instead of funding a massive in-house build, companies that choose NEX will be leveraging a proven platform. This reduces upfront spend and frees resources for strategic investments in drug development, market access, and partnerships.
Launch with Regulatory Confidence
Regulatory alignment is baked into the NEX Platform from the start. This enables your digital launch to keep pace with your commercial strategy, rather than lagging months or years behind it.
In short, NEX helps pharma companies transform their digital companion strategy from a cost center into a competitive advantage.
Why Your GLP-1 Companion App Matters Now
The GLP-1 market is booming. Analysts project exponential growth over the next decade, with new entrants and expanded indications already on the horizon. The companies that succeed here won’t be just those with the best pharmaceuticals. To define yourself and rise to the top of this crowded space, you’ll need a strong digital ecosystem that supports your therapy and sets you apart.
A GLP-1 companion app is central to that digital ecosystem. A well-built app enables companies to:
- Demonstrate real-world value for payers
- Drive patient adherence and satisfaction
- Capture valuable longitudinal data
- Strengthen competitive positioning
- Scale globally with digital infrastructure already in place
The window for early digital leadership is open now, but don’t expect it to stay open forever. As the market matures, companion apps will shift from being a differentiator for your product to something patients and payers simply expect. Acting now provides forward-thinking pharma leaders the chance to define how a quality GLP-1 companion app functions and what features must be included.
Building a Companion App for Pharma: Novo Nordisk, Eli Lilly, and Beyond
Pharma companies bringing a GLP-1 therapy to market face a specific version of the companion-app challenge. The leaders in the space, Novo Nordisk and Eli Lilly among them, have set an expectation that a serious metabolic therapy arrives with a serious digital experience. For a pharma company or a metabolic health business, a GLP-1 companion app is now part of the product, not an accessory.
Sequenex builds these companion apps for pharma and health companies on the NEX platform, engineered under an ISO 13485-certified quality management system and designed to integrate GLP-1 medication schedules with glucose and biosensor data. The result is a branded, regulatory-ready companion app that captures the real-world evidence payers require, while the pharma company retains ownership of the platform, the data, and the patient relationship.
Frequently Asked Questions
What is a GLP-1 companion app?
A GLP-1 companion app is a branded digital application that supports patients on GLP-1 therapy, tracking adherence, integrating glucose and biosensor data, and capturing real-world outcomes. For pharma and health companies, it is the digital layer that surrounds a GLP-1 drug and generates the evidence payers and regulators expect.
What features should a GLP-1 companion app include?
A GLP-1 companion app typically includes medication and dose scheduling, integration with continuous glucose monitors and other biosensors, patient adherence tracking, a clinician or admin portal, secure cloud data storage, and real-world outcomes reporting for payers. The exact feature set depends on the therapy and the company’s reimbursement strategy.
Can a GLP-1 companion app integrate glucose data and medication schedules?
Yes. A well-built GLP-1 companion app integrates medication schedules with glucose and biosensor data in one place, giving patients a unified view and giving the company a connected stream of adherence and outcomes data. On the NEX platform, this device-agnostic integration is built in.
How long does it take to build a GLP-1 companion app?
Building a compliant companion app from scratch can take 12 to 24 months. On a ready-made foundation like the NEX platform, pharma and health companies can launch a branded GLP-1 companion app in months rather than years.
Partner with NEX to Accelerate Your GLP-1 Innovation
To stand out and succeed in the metabolic health market, you need to launch a digital app alongside your pharmaceutical product. But you don’t need to spend years and millions of dollars building a GLP-1 companion app from scratch. NEX provides a secure, compliant, and customizable foundation explicitly designed for connected health and regulated apps.
With NEX, pharma companies, metabolic health clinics, and prescribing networks can launch branded GLP-1 companion apps in months and easily integrate multiple biosensors, while generating real-world evidence to strengthen reimbursement strategies and scale patient engagement globally.
If you’re ready to learn more about how a GLP-1 companion app and the NEX platform can accelerate your market strategy, connect with us today.
